MSH5 ablated mice and uses therefor

Details MSH5 ablated mice and uses therefor MSH5 ablated mice and uses therefor

1999-12-22

2002-09-03

Crouch, Deborah (Department: 1632)

Multicellular living organisms and unmodified parts thereof and

Nonhuman animal

Transgenic nonhuman animal

C800S003000, C800S025000

Reexamination Certificate

active

06444873

ABSTRACT:

FIELD OF THE INVENTION
The invention relates to animals in which the MutS homolog 5 (MSH5) gene is misexpressed and methods of using such animals or cells derived therefrom, e.g., in methods of evaluating fertility treatments.
BACKGROUND OF THE INVENTION
MutS homolog 5 (MSH5) is a member of a family of proteins that are known to be involved in DNA mismatch repair (Modrich, P. & Lahue (1996)
Annu. Rev. Biochem
. 65, 101-133; Kolodner, R. (1996)
Genes Dev
. 10, 1433-1442). Germ line mutations in MSH2, MLH1 and MSH6 cause hereditary non-polyposis colon cancer (HNPCC) or Lynch syndrome (Leach, F. S. et al. (1993)
Cell
75, 1215-1225; Bronner, C. E. et al. (1994)
Nature
368, 258-261; Papadopoulos, N. et al. (1994)
Science
263, 1625-1629; Akiyama, Y. et al. (1997)
Cancer Res.
57, 3920-3923; Miyaki, M. et al. (1997)
Nature Genet
. 17, 271-272). Inactivation of Msh2, Mlh1, Msh6 and Pms2 in mice leads to hereditary predisposition to intestinal and other cancers (de Wind, N.et al. (1995)
Cell
82, 321-330; Reitmair, A. H. et al. (1995)
Nature Genet
. 11, 64-70). Early studies in yeast revealed a role for some of these proteins, including MSH5, in meiosis (Hollingsworth, N. M., et al. (1995)
Genes & Development
9, 1728-1739; Ross-Macdonald, P. & Roeder, G. S. (1994)
Cell
79, 1069-1080). Gene targeting studies in mice confirmed roles for MLH1 and PMS2 in mammalian meiosis (Baker, S. M. et al. (1995)
Cell
82, 309-320; Edelmann, W. et al. (1996)
Cell
85, 1125-1134; Baker, S. M. et al.
Nature Genet
. 13, 336-342).
SUMMARY OF THE INVENTION
The present invention is based, at least in part, on the generation of animals which are homozygous for a null mutation in the MutS homolog 5 (MSH5) gene and the observation that these animals are sterile. Accordingly, the invention features, a non-human animal, in which the gene encoding the MutS homolog 5 (MSH5) protein is misexpressed.
In preferred embodiments the animal, which is preferably a transgenic animal, is a mammal, e.g., a non human primate or a swine, e.g., a miniature swine, a monkey, a goat, or a rodent, e.g., a rat, but preferably a mouse.
In preferred embodiments, expression of the gene encoding the MSH5 protein is decreased as compared to the wild-type animal. For example, the levels of the MSH5 protein can be suppressed by, at least, 50%, 60%, 70%, 80%, 90%, or 100% as compared to the wild-type animal.
In preferred embodiments, misexpression of the gene encoding the MSH5 protein is caused by disruption of the MSH5 gene. For example, the MSH5 gene can be disrupted through removal of DNA encoding all or part of the protein.
In preferred embodiments, the animal can be heterozygous or homozygous for a misexpressed MSH5 gene, e.g., it can be a transgenic animal heterozygous or homozygous for an MSH5 transgene.
In preferred embodiments, the animal is a transgenic mouse with a transgenic disruption of the MSH5 gene, preferably an insertion or deletion, which inactivates the gene product.
In another aspect, the invention features, a nucleic acid molecule which, when introduced into an animal or cell, results in the misexpression of the MSH5 gene in the animal or cell. In preferred embodiments, the nucleic acid molecule, includes an MSH5 nucleotide sequence which includes a disruption, e.g., an insertion or deletion and preferably the insertion of a marker sequence. For example, a nucleic acid molecule can be the targeting construct shown in FIG.
1
.
In another aspect, the invention features, a method of evaluating a fertility treatment. The method includes: administering the treatment to an MSH5 misexpressing animal, e.g., a transgenic mouse, or a cell therefrom; and determining the effect of the treatment on a fertility indication, e.g., sperm count, testicular size, or oocyte morphology, to thereby evaluate the treatment for fertility. The method may be performed in vivo or in vitro.
In preferred embodiments, the animal or cell is an animal or cell described herein. In other preferred embodiments, the method uses a transgenic mouse in which the expression of the MSH5 gene is inhibited. In yet other preferred embodiments, the method uses a cell derived from a transgenic mouse in which the expression of the MSH5 gene is inhibited.
In another aspect, the invention features, a method for identifying a compound which modulates the activity of MSH5. The method includes contacting MSH5 with a test compound and determining the effect of the test compound on the activity of MSH5 to, thereby, identify a compound which modulates MSH5 activity. In preferred embodiments, the activity of MSH5 is inhibited.
In another aspect, the invention features, a method for modulating the activity of MSH5. The method includes contacting MSH5 or a cell expressing MSH5 with a compound which binds to MSH5 in an amount sufficient (e.g., a sufficient concentration) to modulate the activity of MSH5. In preferred embodiments, the activity of MSH5 is inhibited, e.g., the method can be used in contraception.
In another aspect, the invention features, a method of identifying a subject having or at risk of developing a fertility disease or disorder. The method includes obtaining a sample from said subject; contacting the sample with a nucleic acid probe or primer which selectively hybridizes to MSH5 and determining whether aberrant MSH5 expression or activity exists in the sample, thereby, identifying a subject having or at risk of developing a fertility disease or disorder.
In another aspect, the invention features, an isolated cell, or a purified preparation of cells, from an MSH5 misexpressing animal, e.g., an MSH5 misexpressing animal described herein. In preferred embodiments, the cell is a transgenic cell, in which the gene encoding the MSH5 protein is misexpressed. The cell, preferably a transgenic cell can be an oocyte or a spermatocyte.
In preferred embodiments, the cell is heterozygous or homozygous for the transgenic mutant gene.
Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.


REFERENCES:
patent: WO 9901550 (1999-01-01), None
Moreadith et al, 1997, J. Mol. Med., 75: 208-216.*
Mullins et al, 1996, J. Clin. Invest., 98(11): S37-S40.*
Seamark et al, 1994, Reprod. Fert. Dev., 6: 653-657.*
Akiyama Y, et al. “Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred”.Cancer Res.1997 Sep. 15;57 (18):3920-3.
Bawa S, et al., A mutation in the MSH5 gene results in alkylation tolerance.Cancer Res.Jul. 1, 1997; 57(13):2751-20
Baker SM, et al. “Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over.”Nat Genet.Jul. 1996;13(3):336-42.
Baker SM, et al. “Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis.”Cell.Jul 28, 1995; 82(2):309-19.
de Vries SS, et al. “Mouse MutS-like protein Msh5 is required for proper chromosome synapsis in male and female meiosis”.Genes Dev.Mar. 1, 1999;13(5):523-31.
Edelmann W, et al. “Meiotic pachytene arrest in MLH1-deficient mice”.Cell.Jun. 28, 1996;85(7):1125-34.
Hollingsworth NM, et al., “MSH5, a novel MutS homolog, facilitates meiotic reciprocal recombination between homologs inSaccharomyces cerevisiaebut not mismatch repair.”Genes Dev.Jul. 15, 1995; 9(14):1728-39.
Kolodner R. “Biochemistry and genetics of eukaryotic mismatch repair”.Genes Dev.Jun. 15, 1996;10(12):1433-42.
Leach FS, et al. “Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer”.Cell.Dec. 17, 1993;75(6):1215-25.
Miyaki M, et al. “Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer.”Nat Genet.Nov. 1997;17(3):271-2.
Modrich P, et al. “Mismatch repair in replication fidelity, genetic recombination, and cancer biology”.Annu Rev Biochem.1996;65:101-33.
Moreadith RW, et al. “Gene targeting in embryonic stem cells: the new physiology and metabolism”.J Mol Med.Mar. 1997; 75(3):208-16.
Mullins, L, J et al. “Transgenesis in the Rat and Larger Mammals”J. Clin. Invest.1996; 98: s37-s40.
Papadopoulos N, et al. “Mutation of a mutL

Affiliated with

Also associated with

Rating

MSH5 ablated mice and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with MSH5 ablated mice and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MSH5 ablated mice and uses therefor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2904192